Desvenlafaxine Sustained Release (DVS SR)

DRUG3 trials

Sponsors

Wyeth is now a wholly owned subsidiary of Pfizer

Conditions

Depressive Disorder, MajorDiabetic NeuropathiesFibromyalgiaVasomotor Symptoms

Phase 1

Study Evalutating the Pharmacokinetics (PK) and Safety of a Single Dose of Desvenlafaxine Sustained Release (DVS SR)

CompletedNCT00440427

Wyeth is now a wholly owned subsidiary of PfizerDepressive Disorder, Major

Start: 2007-02-28End: 2007-02-28Target: 12Updated: 2007-12-05

Study Evaluating the Potential of DVS SR to Inhibit the CYP2D6 Pathway

CompletedNCT00456898

Wyeth is now a wholly owned subsidiary of PfizerDepressive Disorder, Major, Diabetic Neuropathies, Fibromyalgia +1

Start: 2007-01-31End: 2007-03-31Target: 40Updated: 2007-12-28

Phase 2

A Study Evaluating Desvenlafaxine Sustained Release (DVS SR) in Adult Female Outpatients With Fibromyalgia

TerminatedNCT00696787

Wyeth is now a wholly owned subsidiary of PfizerFibromyalgia

Start: 2008-06-30End: 2009-01-31Updated: 2013-02-25